Frost & Sullivan Research Service   Published: 18 May 2012
Analysis of the European Bipolar-disorder Therapeutics Market
  SERVICE HOMEPAGE
RESEARCH OVERVIEW TABLE OF CONTENTS ORDERING INFORMATION
FURTHER INFORMATION
   Research Overview
 

This Frost & Sullivan research titled Analysis of the European Bipolar-disorder Therapeutics Market provides an assessment of the market, maps the key trends and dynamics shaping the industry, offers valuable insights on pipeline analysis and competitive landscape and gives strategic recommendations to succeed in the market. The study segment the market in terms of the three major classes of drugs used for treatment—atypical antipsychotics, mood stabilisers and anti-depressants—with a focus on the key five countries in Europe: Germany, France, the United Kingdom, Italy and Spain.

This analysis is available through our Life Sciences Growth Partnership Services programme. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services programme ensures that you and your Growth Team™ are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth. For more information on this custom subscription service, please click here.

Market Overview

European Bipolar-disorder Therapeutics Market Expected to See Significant Growth Opportunities Beyond 2013

Bipolar disorder is a serious economic burden to European healthcare. For instance, the average annual expenditure for 2011 was €38,547 million with indirect costs accounting for 60-80 per cent of the total costs incurred. However, patent expiry of key blockbuster drugs has caused a dip in the bipolar disorder therapeutics market. “Patent expiry of several key blockbuster atypical antipsychotics, including Seroquel from Astrazeneca, the only approved atypical antipsychotic for both bipolar mania and depression, is one of the key challenges for the market participants,” notes the analyst of this research. “As generic equivalents of these blockbuster drugs reach the market, drug prices are expected to fall between 30–60 per cent, causing an overall decrease of 10.1 per cent in the European bipolar disorder therapeutics market until 2013.”

This situation will change beyond 2013 as novel formulations and improved depot formulations present robust growth opportunities. The key driver for the development will be the high levels of unmet therapeutic needs in the market. Most of the currently approved drugs focus on the treatment of acute mania or hypomania, which means that drugs targeting bipolar depression are the need of the hour. “Any initiative to develop new and improved drug formulations – particularly depot formulations of atypical antipsychotics that improves the efficacy, safety and overall performance of the drug – will bear fruit in the coming years,” said the analyst. “Increasing investments in R&D and the commercialisation of four potential product candidates within the next few years too will brighten growth prospects.”

Frost & Sullivan Growth Partnership Services

Frost & Sullivan's Growth Partnership Services empower companies to accelerate their growth by achieving top-line improvements and bottom-line results. This is accomplished by helping our clients execute successful growth strategies and providing their Growth Teams™ with the skills, know-how, and tools to generate growth opportunities, evaluate these opportunities to create a growth pipeline, and implement a growth strategy to deliver measurable business results.

Our growth solutions support the entire growth process:

TEAM Research is a program that furnishes clients with access to market research, competitive intelligence, financial benchmarking, and market strategies and analysis, and provides access to industry experts to aid in generating growth opportunities.

Growth Consulting Services unite clients with our industry experts to evaluate opportunities and develop customized strategies and business plans to drive top-line revenue and margin growth.

Growth Team Membership™ is a career-focused offering that was developed to address the unique challenges that senior executives face when implementingstrategies to achieve aggressive corporate growth targets.

  Table Of Contents
  1 | EXECUTIVE SUMMARY
   Summary of the European Bipolar-disorder Therapeutics Market
      1. Executive Summary

  2 | INTRODUCTION
   Introduction to the European Bipolar-disorder Therapeutics Market
      1. Research Scope and Objectives
      2. Bipolar-disorder Disease Segmentation
      3. Geographic Scope

  3 | MARKET OVERVIEW
   Overview of the European Bipolar-disorder Therapeutics Market
      1. Market Overview

  4 | INTRODUCTION TO BIPOLAR DISORDER
   Introduction to Bipolar-disorder Disease
      1. Bipolar Disorder- Definition
      2. Signs and Symptoms
      3. Diagnosis
      4. Diagnostic Scales for Bipolar-disorder
      5. Risk Factors

  5 | MANAGEMENT OF BIPOLAR DISORDER
   Management of Bipolar Disorder - Drugs Used and Treatment Regimen
      1. Classification of Drugs
      2. Treatment of Acute Mania
      3. Treatment of Depression
      4. Treatment of Mixed Episodes and Maintenance Phase
      5. Psychological Intervention

  6 | EPIDEMIOLOGY
   Epidemiology of Bipolar Disorder in Europe
      1. Demographics by Country
      2. Prevalence of Mood Disorders in Europe
      3. Prevalence and Mortality Rates of Bipolar Disorder by Age and Gender
      4. Lifetime Prevalence of Co-morbidities with Bipolar Disorder
      5. Bipolar-disorder Treatment Statistics in Europe

  7 | EXTERNAL CHALLENGES: MARKET DRIVERS AND RESTRAINTS FOR THE TOTAL MARKET
   Industry Challenges, Market Drives and Restraints of the European Bipolar-disorder Therapeutics Market
      1. Industry Challenges- Impact and Duration
      2. Market Drivers and Restraints
      3. Impact Mapping of Drivers and Restraints

  8 | MARKET TRENDS AND REVENUE FORECASTS FOR THE TOTAL MARKET
   Measurements and Revenue Forecasts
      1. Measurements
      2. Forecast Assumptions
      3. Total Bipolar-disorder Therapeutics Market Revenue Forecast
      4. Total Bipolar-disorder Therapeutics Market Revenue Forecast Discussion
      5. Bipolar-disorder Therapeutics Market Per Cent of Revenue by Country

  9 | COMPETITIVE LANDSCAPE ANALYSIS
   Analysis of the Competitive Landscape of the European Bipolar-disorder Therapeutics Market
      1. Competitive Structure
      2. Competitive Analysis: Profiling of Selected Key Market Participants
      3. Competitive Analysis: Promising Companies in the Future
      4. Bipolar-disorder Therapeutics Market Competitive Landscape

  Analysis of the Marketed Products for Bipolar Disorder
      1. Marketed Product Analysis — Bipolar-disorder Medication
      2. Marketed Product Analysis — Key Patent Expiries

  10 | PIPELINE ANALYSIS
   Analysis of Potential Bipolar Drug Candidates in Pipeline
      1. Late-stage Product Analysis
      2. Pipeline Analysis

  11 | COST ANALYSIS
   Cost Analysis of the European Bipolar-disorder Therapeutics Market
      1. Economic Burden Due to Mood Disorders in Europe
      2. Cost Analysis of Mood Disorders
      3. Cost Analysis of Bipolar Disorders

  12 | REGULATORY ANALYSIS
   Regulatory Analysis of the European Bipolar-disorder Therapeutics Market
      1. The EU Regulatory Framework for Bipolar Disorders
      2. Efficacy Criteria
      3. Study Population and Design
      4. Therapeutic Studies
      5. Safety Aspects

  13 | ATYPICAL ANTIPSYCHOTIC DRUGS SEGMENT BREAKDOWN
   Analysis of the Atypical Antipsychotic Drugs Segment for Bipolar Disorder
      1. Measurements
      2. Atypical Antipsychotic Drugs Segment Revenue Forecast
      3. Atypical Antipsychotic Drugs Segment Revenue Forecast Discussion
      4. Atypical Antipsychotic Drugs Segment End-user Analysis
      5. Atypical Antipsychotic Drugs Segment - A Physician's Perception
      6. Atypical Antipsychotic Drugs Segment Competitive Analysis—Market Share
      7. Atypical Antipsychotic Drugs Segment Market Share Analysis
      8. Atypical Antipsychotic Drugs Segment - Key Marketed Product Analysis

  14 | MOOD-STABILISING DRUGS
   Analysis of the Mood-stabilising Drugs Segment for Bipolar Disorder
      1. Measurements
      2. Mood-stabilising Drugs Segment Revenue Forecast
      3. Mood-stabilsing Drugs Segment Revenue Forecast Discussion
      4. Mood-stabilising Drugs Segment End-user Analysis
      5. Mood-stabilising Drugs Segment - A Physician's Perspective
      6. Mood-stabilising Drugs Segment Competitive Analysis—Market Share
      7. Mood-stabilising Drugs Segment Market Share Analysis
      8. Mood-stabilising Drugs Segment - Key Marketed Products Analysis

  15 | ANTI-DEPRESSANT DRUGS SEGMENT BREAKDOWN
   Analysis of the Anti-depressant Drugs Segment for Bipolar Disorder
      1. Measurements
      2. Anti-depressant Drugs Segment Revenue Forecast
      3. Anti-depressant Drugs Segment Revenue Forecast Discussion
      4. Anti-depressanr Drugs Segment End-user Analysis
      5. Anti-depressant Drugs Segment - A Physician's Perspective
      6. Anti-depressant Drugs Segment Competitive Analysis—Market Share
      7. Anti-depressant Drugs Segment - Market Share Analysis
      8. Anti-depressant Drugs Segment - Key Marketed Products Analysis

  16 | GERMANY BREAKDOWN
   Germany Bipolar-disorder Therapeutics Market
      1. Germany Market - Market Engineering Measurements
      2. Germeny Market Revenue Forecast

  17 | FRANCE BREAKDOWN
   France Bipolar-disorder Therapeutics Market
      1. France Market - Market Engineering Measurements
      2. France Market Revenue Forecast

  18 | THE UNITED KINGDOM BREAKDOWN
   The United Kingdom Biolar-disorder Therapeutics Market
      1. The United Kingdom Market - Market Engineering Measurenments
      2. The United Kingdom Market Revenue Forecast

  19 | ITALY BREAKDOWN
   Italy Bipolar-disorder Therapeutics Market
      1. Italy Market - Market Engineering Measurements
      2. Italy Market Revenue Forecast

  20 | SPAIN BREAKDOWN
   Spain Bipolar-disorder Therapeutics Market
      1. Spain Market - Market Engineering Measurements
      2. Spain Market Revenue Forecast

  21 | THE LAST WORD
   Conclusions and Implications
      1. The Last Word—Three Big Predictions

  22 | SUMMARY OF MAJOR FINDINGS
   Summary of Major Findings of the European Bipolar-disorder Therapeutics Market
      1. Summary of Major Findings

  23 | APPENDIX
   Support Databases
      1. Methodology
      2. Decision Support Databases
      3. List of Abbreviations
      4. Database of Key Industry Participants

  More Information
Please print out this form, complete your details and fax it to Frost & Sullivan:
Latin & North America:
Frost & Sullivan
Sales Department
7550 West Interstate 10
Suite 400
San Antonio
Texas 78229-5616. USA
Fax: 888.690.3329
Asia Pacific:
Frost & Sullivan
Sales Department
100 Beach Road
#29-01/11, Shaw Tower
Singapore 189702
SINGAPORE
Fax: +65 68900988
EMEA:
Frost & Sullivan
Sales Department
Sullivan House
4 Grosvenor Gardens
London SW1W 0DH. UK
Fax: +44(0) 1865 389 515
SERVICE INQUIRY


I would like information on:
Analysis of the European Bipolar-disorder Therapeutics Market (M855-01-00-00-00)

YOUR DETAILS

Name Address
Title
Company
Telephone State/Province
Fax Zip/Postal Code
Email Country
Select the markets that interest you Tell us the services that interest you
Aerospace & Defense
Automotive & Transportation
Business & Financial Services
Career Research
Chemicals, Materials & Foods
Consumer Products
Education
Electronics and Security
Energy & Power Systems
Environment & Building Technologies
Healthcare
Industrial Automation
Information & Communication Tech.
Measurement & Instrumentation
Metals & Minerals
 
Growth Partnership Services
Growth Team Membership
Growth Strategy Dialogue
Growth Consulting
Growth Workshops
Events
Corporate Training & Development
Best Practices Research
Technical Research
Econometric Research
Market Engineering Research
Customer Research
Financial Benchmarking & Analysis
Stratecast: Telecoms Strategic Forecasting
Career Opportunities
Press Support Services
Comments: (For instance 'Please send me more information on...')

  Further Information

Enquiries from:
Africa:
Tel:+27 21 680 3260
Email: enquiries@frost.com

Enquiries from:
Asia Pacific:
Tel: +65 68900999
Email: apacfrost@frost.com
 
Enquiries from:
Europe:
Tel: +44 (0) 20 7343 8383
Email: enquiries@frost.com
Enquiries from:
Latin America:
Tel: +54 11 4777 1550
Email: myfrost.la@frost.com
 

Enquiries from:
Middle East and North Africa:
Tel: +971.4.4331.893
Email: meenquiries@frost.com

Enquiries from:
North America:
Tel:+1.877.GO.FROST (463.7678)
Email: enquiries@frost.com
 

Enquiries from:
South Asia:
Tel: +91 (0) 22 6160 6666
Email: safrost@frost.com




 
For a full list of our offices click here.
 
Conseq